Clinical Trial Update: NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update evaluating nanoliposomal irinotecan with XELOX plus cadonilimab (AK104) as first-line treatment for advanced pancreatic cancer, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• Cadonilimab
• Capecitabine (capecitabine)
• Nanoliposomal irinotecan (irinotecan liposomal)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Conditions: Nanoliposomal Irinotecan, Cadonilimab | Phase 2 | Status: RECRUITING